Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insmed Incorporated before investing.

In this article, we go over a few key elements for understanding Insmed Incorporated’s stock price such as:

• Insmed Incorporated’s current stock price and volume
• Why Insmed Incorporated’s stock price changed recently
• Upgrades and downgrades for INSM from analysts
• INSM’s stock price momentum as measured by its relative strength

About Insmed Incorporated (INSM)

Before we jump into Insmed Incorporated’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Want to learn more about Insmed Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insmed Incorporated.

Insmed Incorporated’s Stock Price as of Market Close

As of May 14, 2026, 9:47 AM, CST, Insmed Incorporated’s stock price was $115.850.

Insmed Incorporated is down 1.81% from its previous closing price of $117.990.

During the last market session, Insmed Incorporated’s stock traded between $115.105 and $119.090. Currently, there are approximately 215.47 million shares outstanding for Insmed Incorporated.

Insmed Incorporated’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insmed Incorporated Stock Price History

Insmed Incorporated’s (INSM) price is currently down 15.02% so far this month.

During the month of May, Insmed Incorporated’s stock price has reached a high of $142.900 and a low of $98.900.

Over the last year, Insmed Incorporated has hit prices as high as $212.750 and as low as $64.845. Year to date, Insmed Incorporated’s stock is down 33.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insmed Incorporated Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2026, there were 0 analysts who downgraded Insmed Incorporated’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insmed Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insmed Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Insmed Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insmed Incorporated (INSM) by visiting AAII Stock Evaluator.

Relative Price Strength of Insmed Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2026, Insmed Incorporated has a weighted four-quarter relative price strength of 8.58%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how Insmed Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insmed Incorporated Stock Price: Bottom Line

As of May 14, 2026, Insmed Incorporated’s stock price is $115.850, which is down 1.81% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insmed Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.